Skip Ribbon Commands
Skip to main content

Find A Doctor

Dr Tan Poh Seng

Photo of Dr Tan Poh Seng
Credential:
MBBS (Hons), MRCP (UK), M.Med (S'pore), FAMS (Gastroenterology)
Designation:
Senior Consultant, Division of Gastroenterology and Hepatology, University Medicine Cluster, National University Hospital
Director of Clinical Services, Division of Gastroenterology and Hepatology, University Medicine Cluster, National University Hospital
Senior Consultant, Liver Transplantation, National University Centre for Organ Transplantation, National University Hospital
Assistant Professor, Yong Loo Lin School of Medicine, National University of Singapore
Senior Advisor, NUH Medical Board
Senior Consultant, National University Cancer Institute, Singapore 
HPB Tumour Group Lead
Specialty:
Cancer, Medicine, Organ Transplantation
Sub Specialty:
Gastroenterology & Hepatology, Liver Transplantation
Medical and Surgical Conditions:
Autoimmune Hepatitis, Bile Duct Cancer, Colonic Diverticulosis, Functional Dyspepsia, Gallbladder Cancer, Gastroesophageal Reflux Disease (GERD), Gilbert's Syndrome, Helicobactor Pylori, Hepatitis B, Hepatitis C, Hepatocellular Carcinoma, Inflammatory Bowel Disease (IBD), Liver Cancer, Liver Cirrhosis, Liver Transplant, Non-alcoholic Steatohepatitis (NASH), Pancreatic Cancer, Primary Biliary Cirrhosis (PBC), Ulcerative Colitis
Special Interest:
General Gastroenterology and Hepatology
Liver Transplant
Liver Cancer
Viral Hepatits
Institution:
National University Hospital
National University Cancer Institute, Singapore
National University Health System
Dr Tan graduated from the University of Melbourne in Australia (MBBS) with an honours degree in 2003 and returned to Singapore for his postgraduate training in 2004. He completed his basic specialist training and obtained the Membership of the Royal College of Physicians MRCP (UK), as well as his Master of Medicine (Singapore) in 2007. Dr Tan received further advanced specialist training in Gastroenterology & Hepatology and was certified by the Specialists Accreditation Board of Singapore in 2011. He further undertook his fellowship and research training in advanced hepatology and transplant hepatology at the Recanati/Miller Transplantation Institute and the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai (New York, USA).

Dr Tan’s clinical expertise includes advanced liver diseases, viral hepatitis, fatty liver, liver cirrhosis, liver cancer and liver transplantation, in addition to common digestive diseases and endoscopic procedures. He has authored or co-authored numerous research publications and is the principal investigator for ongoing clinical studies in the field of liver transplantation, immunosuppression and hepatocellular carcinoma. As an Assistant Professor at the NUS Yong Loo Lin School of Medicine and a core faculty member of the Senior Residency Programme in Gastroenterology & Hepatology, Dr Tan is actively engaged in undergraduate and post-graduate medical education.

Beyond clinical and academic work, Dr Tan is also involved in administrative duties in his capacities as Senior Advisor to the NUH Medical Board and Deputy Patient Safety Officer, assisting the hosptal with clinical risk management in leading quality and safety initiatives within University Medicine Cluster respectively.

Awards and Honours

Top scored poster ILCA 2014
Academic Medicine Development Award 2013
National Scholar Award at the United European Gastroenterology Week in 2011

Research and Publications

  1. Tan PS, Nakagawa S, Goossens N, Venkatesh A, Huang T, Ward SC, Sun X, Song W, Koh A, Canasto-Chibuque C, Deshmukh M, Nair V, Mahajan M, Zhang B, Fiel MI, Kobayashi M, Kumada H, Hoshida Y. Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver Int. 2015
  2. Poh Seng Tan, Badar Muneer, Smruti R. Mohanty, et al. Hepatoma. BMJ Best Practice 2016 Update.
  3. Poh Seng Tan, Myat Oo Aung, Seng Gee Lim, et al. Liver disease progression and virological response: entecavir rescue still possible in the setting of rtM204I lamivudine resistant mutation. Gut 2012;62(5):801-802.
  4. Hartono JL, Koh T, Lee GH, Tan PS, Muthiah M, Aw MM, Madhavan K, Kow A, Lim KBL. Predictors of Non-adherence to Immunosuppressive Therapy in Asian Liver Transplant Recipients. Transplant Proc. 2017 Jul - Aug;49(6):1419-1424
  5. Taouli B, Hoshida Y, Kakite S, Chen X, Tan P, Sun X, Kihira S, Kojima K, Toffanin S, Fiel MI, Hirschfield H, Wagner M, Llovet JM. Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results. Eur Radiol. 2017
  6. Miltiadous O, Sia D, Hoshida Y, Fiel MI, Harrington AN, Thung SN, Tan PS, Dong H, Revill K, Chang CY, Roayaie S, Byrne TJ, Mazzaferro V, Rakela J, Florman S, Schwartz M, Llovet JM. Progenitor cell markers predict outcome of patients with Hepatocellular Carcinoma beyond Milan criteria undergoing liver transplantation. J Hepatol. 2015 Jul 25. pii: S0168-8278(15)00516-4. doi: 10.1016/j.jhep.2015.07.025.
  7. King LY, Canasto-Chibuque C, Johnson K, Yip S, Chen X, Kojima K, Deshmukh M, Venkatesh A, Tan P, Sun X, Villanueva A, Sangiovanni A, Nair V, Mahajan M, Kobayashi M, Kumada H, Iavarone M, Colombo M, Fiel MI, Friedman SL, Llovet JM, Chung RT, Hoshida Y. A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut 2014
  8. SG Lee GH, Lim K, Tan PS. RESISTANCE IS NO LONGER A PROBLEM WITH ENTECAVIR AND TENOFOVIR. Current Hepatitis Reports 2013.